Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
Clinical trial NCT02370888 · TERMINATED
Trial details
- NCT number
- NCT02370888
- Sponsor
- University of Florida
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-16
- Primary completion
- 2019-05-31
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.